Clinical trials for Squamous cell carcinoma of the esophagus
100 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT07457528Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCCTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPhase 2NCT07331155A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]Nanjing Leads Biolabs Co.,Ltd · PI: Lin Shen
- RECRUITINGPhase 1NCT07503808A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesIDEAYA Biosciences
- RECRUITINGPhase 2NCT07403136Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCCFudan University
- RECRUITINGPHASE1, PHASE2NCT07385001A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCCTang-Du Hospital
- RECRUITINGPhase 2NCT07263919Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)Akeso · PI: Xiaolong Yan
- RECRUITINGPhase 2NCT07481058KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal CancerBeijing Konruns Pharmaceutical Co., Ltd.
- RECRUITINGPhase 1NCT07217171A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell CarcinomasEvolveImmune United, Inc · PI: EvolveImmune Study Team
- ENROLLING BY INVITATIONPhase 2NCT07312578Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell CarcinomaPeking University · PI: Zhihao MM Lu, PHD
- RECRUITINGPhase 2NCT07039162Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell CarcinomaMing-Yu Lien
- RECRUITINGPhase 2NCT07290010The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell CarcinomaHebei Medical University Fourth Hospital
- RECRUITINGPHASE1, PHASE2NCT06753747A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell CarcinomaWest China Hospital · PI: Jin Zhou
- RECRUITINGPhase 1NCT07085091A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsALX Oncology Inc.
- RECRUITINGPhase 2NCT07162506DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCITianjin Medical University Cancer Institute and Hospital · PI: Wencheng Zhang, M.D.
- RECRUITINGPHASE1, PHASE2NCT06780111Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)Merck Sharp & Dohme LLC · PI: Medical Director
- RECRUITINGPhase 2NCT06764355Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell CarcinomaNational Taiwan University Hospital
- RECRUITINGPhase 2NCT07086469Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell CarcinomaSun Yat-sen University · PI: Hui Liu
- RECRUITINGPhase 1NCT07317609Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)Shanghai Zhongshan Hospital
- RECRUITINGPhase 2NCT07188103Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell CarcinomaAnhui Provincial Hospital
- RECRUITINGPhase 1NCT07359417MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell CarcinomaUMC Utrecht
- RECRUITINGPhase 2NCT06908382Neoadjuvant QL1706 Therapy for ESCCShandong Provincial Hospital
- RECRUITINGPhase 2NCT06912074Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell CarcinomaSun Yat-sen University · PI: Hui Liu, Professor
- RECRUITINGPhase 2NCT06843889A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell CarcinomaNanfang Hospital, Southern Medical University
- RECRUITINGPhase 3NCT06644781A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)Daiichi Sankyo
- ACTIVE NOT RECRUITINGPhase 2NCT06888531Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell CarcinomaHenan Cancer Hospital
- RECRUITINGPhase 2NCT07038629Chemoradiation Plus Iparomlimab Consolidation in Older With ESCCTianjin Medical University Cancer Institute and Hospital · PI: Wencheng Zhang, M.D.
- RECRUITINGNCT07088354Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant ImmunochemotherapyTongji Hospital · PI: Yangkai Li, MD, PhD
- RECRUITINGPhase 3NCT06964568CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCCFudan University
- RECRUITINGPhase 2NCT06769113A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard TherapyShanghai Henlius Biotech · PI: Jinming Yu, Dr.
- RECRUITINGPHASE1, PHASE2NCT06747585A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid TumorsAlentis Therapeutics AG
- RECRUITINGN/ANCT07430579Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell CarcinomaThe Second Hospital of Shandong University · PI: Yunpeng Zhao, doctor
- ENROLLING BY INVITATIONN/ANCT06715501Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell CarcinomaFirst Affiliated Hospital of Ningbo University
- RECRUITINGPhase 2NCT06489197AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma PatientsTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPhase 3NCT06676449TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCCFudan University
- RECRUITINGPhase 2NCT06709417A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)Shanghai Chest Hospital
- RECRUITINGPhase 2NCT06684600Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell CarcinomaPeking University · PI: Zhihao Lu, MD
- ACTIVE NOT RECRUITINGN/ANCT06762158NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCCRenJi Hospital
- RECRUITINGPhase 2NCT06637163Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCCShanghai Zhongshan Hospital · PI: Lijie Tan, Professor
- RECRUITINGNCT06710665Tumor Regression Grade As Predictor of Adjuvant TherapyFujian Medical University Union Hospital · PI: Bin Zheng
- RECRUITINGPhase 2NCT06663059Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles StudyTang-Du Hospital · PI: Tao Jiang, Dr
- RECRUITINGPhase 2NCT07437898Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical StudyThe Affiliated Hospital of Putian University
- RECRUITINGNCT06561178Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)Sun Yat-Sen University Cancer Center · PI: Hong Yang, M.D.;Ph.D.
- ENROLLING BY INVITATIONN/ANCT06863831A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for ECCancer Institute and Hospital, Chinese Academy of Medical Sciences · PI: Li Feng, Ph.D.
- RECRUITINGPhase 2NCT07016724Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell CancerThe First Affiliated Hospital of Zhengzhou University · PI: Xiangbo Wan
- RECRUITINGPhase 2NCT06576973Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell CarcinomaSecond Affiliated Hospital, School of Medicine, Zhejiang University · PI: Wang
- RECRUITINGPhase 1NCT06654297Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell CarcinomasWest China Hospital
- ENROLLING BY INVITATIONPhase 3NCT07016737Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive ChemoradiotherapyYe jinjun · PI: Ye jin jiun
- RECRUITINGPhase 2NCT06601309Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCCFujian Medical University Union Hospital
- RECRUITINGPhase 2NCT06385730Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)Shanghai Chest Hospital
- RECRUITINGPhase 2NCT06885814Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell CarcinomaNanfang Hospital, Southern Medical University
- RECRUITINGPhase 2NCT06413342Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell CarcinomaZhejiang Cancer Hospital · PI: Yongling Ji
- RECRUITINGPhase 2NCT06354140PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDYDaping Hospital and the Research Institute of Surgery of the Third Military Medical University
- RECRUITINGPhase 2NCT06510660Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCCFujian Medical University Union Hospital · PI: Yong Yang, Doctor
- RECRUITINGNCT06698692Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell CarcinomaThe First Affiliated Hospital with Nanjing Medical University · PI: Xiao L Ge, PHD
- RECRUITINGPhase 2NCT06646588Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell CarcinomaHebei Medical University Fourth Hospital
- ACTIVE NOT RECRUITINGPhase 3NCT06304974A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaSichuan Baili Pharmaceutical Co., Ltd. · PI: Lin Shen, PHD
- ACTIVE NOT RECRUITINGPhase 2NCT06247956Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal CancerSuzhou Suncadia Biopharmaceuticals Co., Ltd.
- RECRUITINGPhase 2NCT06339619Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell CarcinomaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- RECRUITINGPHASE2, PHASE3NCT06354530A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell CarcinomaArmy Medical Center of PLA · PI: Jingjing Wang
- RECRUITINGPhase 2NCT06187597Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)Sun Yat-sen University · PI: Mian Xi, MD
- RECRUITINGNCT06408584Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and TislelizumabAnhui Provincial Hospital
- RECRUITINGPhase 2NCT06272214Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of ImmunotherapyZhejiang Cancer Hospital · PI: Youhua Jiang, M.D.
- RECRUITINGN/ANCT06602843Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative RadioimmunotherapyAnhui Provincial Hospital
- RECRUITINGPhase 2NCT07266493Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaShanghai Zhongshan Hospital
- RECRUITINGNCT06169163Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal NeoplasmsImperial College London
- ACTIVE NOT RECRUITINGPhase 2NCT06281886Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell CarcinomaSun Yat-sen University · PI: Hui Liu, Professor
- ACTIVE NOT RECRUITINGPhase 2NCT06010303A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaBeiGene · PI: Study Director
- RECRUITINGPhase 2NCT06190639A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCCZhejiang Cancer Hospital
- RECRUITINGPhase 3NCT06022861A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell CarcinomaShandong Boan Biotechnology Co., Ltd
- RECRUITINGPhase 2NCT06061146Tislelizumab Plus Concurrent Chemoradiation in Older With ESCCTianjin Medical University Cancer Institute and Hospital · PI: Wencheng Zhang, M.D
- RECRUITINGPhase 2NCT06056336Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell CarcinomaGuo Xufeng · PI: Changqing Pan
- ACTIVE NOT RECRUITINGPhase 1NCT06020885Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.Sun Yat-sen University · PI: Hui Liu, Professor
- RECRUITINGPhase 2NCT06603402Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCCSichuan University · PI: zhenyu ding, MD
- RECRUITINGPhase 1NCT05984342Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell CarcinomaAffiliated Cancer Hospital of Shantou University Medical College
- RECRUITINGPHASE1, PHASE2NCT05473156A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected MalignanciesAP Biosciences Inc.
- RECRUITINGPhase 3NCT05919030A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell CarcinomaRenmin Hospital of Wuhan University
- RECRUITINGNCT05833594Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell CarcinomaAnhui Provincial Hospital
- RECRUITINGPhase 2NCT06186609PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCCAffiliated Hospital of Nantong University · PI: Yu Weiwei
- RECRUITINGPHASE1, PHASE2NCT05319730A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)Merck Sharp & Dohme LLC · PI: Medical Director
- RECRUITINGNCT05894369Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell CarcinomaRenmin Hospital of Wuhan University
- RECRUITINGPhase 2NCT05738434Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCCThe First Affiliated Hospital of Zhengzhou University · PI: Feng Wang, phD
- RECRUITINGN/ANCT05760391A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.Fudan University
- RECRUITINGPHASE1, PHASE2NCT06173986Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal CancerShanghai Chest Hospital · PI: Wen Yu, M.D
- ACTIVE NOT RECRUITINGPhase 2NCT05659251Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell CarcinomaSecond Affiliated Hospital, School of Medicine, Zhejiang University · PI: Weilin Wang
- ACTIVE NOT RECRUITINGN/ANCT05951127Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCCCancer Institute and Hospital, Chinese Academy of Medical Sciences · PI: Yin Li, M.D.
- RECRUITINGPhase 3NCT05357846PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)Sun Yat-sen University · PI: HONG YANG
- RECRUITINGPhase 2NCT06122493Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell CarcinomaRuijin Hospital
- RECRUITINGPhase 1NCT05208762A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsSeagen, a wholly owned subsidiary of Pfizer · PI: Pfizer CT.gov Call Center
- RECRUITINGPhase 3NCT06190782Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 InhibitorFudan University · PI: Kuaile Zhao, MD
- RECRUITINGPhase 2NCT06006650Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous CellTang-Du Hospital · PI: Xiaolong Yan, MD
- RECRUITINGNCT05392413Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal AntibodyNanfang Hospital, Southern Medical University · PI: Lei Zheng
- RECRUITINGPhase 3NCT05495152Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell CarcinomaHenan Cancer Hospital
- ENROLLING BY INVITATIONN/ANCT06048926Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell CarcinomaThe First Affiliated Hospital with Nanjing Medical University · PI: Xiaolin MM GE
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT06303583Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell CarcinomaQiu Guoqin
- ACTIVE NOT RECRUITINGNCT07147361Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell CarcinomaCancer Institute and Hospital, Chinese Academy of Medical Sciences · PI: Department of Etiology and Carcinogenesis
- RECRUITINGPHASE2, PHASE3NCT04973306Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCCShanghai Zhongshan Hospital · PI: Lijie Tan, MD
- ACTIVE NOT RECRUITINGNCT06472635a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC StudyZhejiang University
- RECRUITINGPhase 2NCT05182944A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCCThe First Affiliated Hospital of Zhengzhou University · PI: Song Zhao
- ACTIVE NOT RECRUITINGPhase 2NCT05022654SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.Sichuan Baili Pharmaceutical Co., Ltd. · PI: Lin Shen
- RECRUITINGPhase 3NCT04807673Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)Tianjin Medical University Cancer Institute and Hospital